All
Outcomes
Market
Price
AI Fair
Value
Value
Edge
YesNo
AI Insights:
03.06 17:30 UpdatedFair Value Reasoning:
While sporadic Nipah virus cases occurred in India (West Bengal) and Bangladesh in early 2026, the latest epidemiological data confirms the outbreaks are contained. All contacts traced by Indian authorities (>190) and in Bangladesh (35) tested negative, with no new cases reported since late January. Both WHO and CDC assess the transmission risk to the US as 'very low,' and no specific high-level travel warnings have been issued. Given Nipah's limited transmissibility (requiring close contact or contaminated food) and only ~25 days remaining until expiration, the probability of a confirmed case emerging in the US without any current active transmission chains or suspected imports is near zero (<1%). The current market price of ~3 cents represents a significant overestimation of this tail risk.
Sign up to view more information
Exotics
While Nipah is a known deadly pathogen, it is not a current global pandemic focus (like COVID-19 or flu). Predicting the importation of this specific rare tropical disease into the US within a short timeframe represents a niche tail-risk event with moderate attention.
Hedging
MRNA
If a confirmed Nipah case is reported in the US by March 31, while it may not immediately lead to COVID-style lockdowns, it would trigger fears of a new pandemic, increasing risk aversion. Major vaccine stocks (e.g., Moderna, Pfizer) could see speculative gains (Impact 3) due to potential R&D needs, while the broader market (S&P 500) might experience a minor panic sell-off (Impact 2). Given Nipah's high mortality rate, even a single case is sufficient to generate significant media attention and localized market reaction.
Divergence
Significant divergence exists. Prediction market pricing implies a ~3% probability of a Nipah case in the US within the next three weeks, whereas mainstream scientific consensus (WHO, CDC) and epidemiological data suggest the risk is 'very low' and essentially near zero. The market price is driven more by general news-induced panic than by specific evidence of transmission.
